Divalproex Sodium Tablet, Delayed Release
Product Images NDC 51655-365

7 FDA label images from Northwind Health Company, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 51655-365). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 01)

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 01)
Chemical structure of divalproex sodium showing the sodium salt form of valproic acid dimer with carboxylate groups and hydrocarbon chains.*
FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 02)

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 02)
A bar chart comparing percentages of two groups labeled PBO and DVPX across two studies, Study 1 (YMRS) and Study 2 (MRS). The chart shows the DVPX group reaching 60% and 58%, while the PBO group reaches 26% and 29% respectively.*
FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 03)

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 03)
A cumulative percentage plot showing % reduction in clinical pain score (CPS) rate on the vertical axis against % of patients on the horizontal axis. Two lines are displayed: a solid line for Divalproex Sodium and a dotted line for Placebo, illustrating comparative patient response rates from worsening to improvement.*
FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 04)

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 04)
A line graph comparing the percentage reduction in CPS rate versus the percent of patients for High Dose and Low Dose Divalproex Sodium. The y-axis shows percent reduction in CPS rate from -100% to 100%, and the x-axis shows percent of patients from 0 to 100%. The graph includes a note indicating 'Improvement' above and 'Worsening' below the y-axis baseline of zero change.*
FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 05)

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 05)
A bar chart comparing Placebo and Divalproex Sodium treatments in two studies, labeled Study 1 and Study 2. The vertical axis measures a variable ranging from 0 to 6, showing higher values for Placebo groups compared to Divalproex Sodium groups in both studies.*
FDA Label Image

Image (674e58bd F580 4805 A7e2 Febcaa37bca5 1830 2)

FDA Label Image

Label (51655 365 52 Rev A 05 20 Nhc)

Label (51655 365 52   Rev A 05 20 Nhc)
Label for Divalproex Sodium delayed release tablets, USP 250 mg from Northwind Health Company, LLC. The label specifies 30 tablets per container, for oral use with Rx only. Storage instructions and safety notes like keeping out of reach of children are included, along with a lot number and expiration date area.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.